



Media Contact
Dan McFadden
dmcfadden@oculusis.com
(425) 836-3103

OCULUS INNOVATIVE SCIENCES FILES APPLICATION WITH U.S. ENVIRONMENTAL PROTECTION AGENCY FOR APPROVAL OF MICROCYN™ AS A HOSPITAL-GRADE DISINFECTANT

Approval by EPA would permit the use of Microcyn™ disinfectant in households, hospitals and industrial environments.

PETALUMA, CA-- (May 14, 2004)— Oculus Innovative Sciences announced today that the company has filed its application with the U.S. Environmental Protection Agency for approval of the company's revolutionary Microcyn™ disinfectant as a hospital-grade disinfectant for use in households, hospitals and industrial environments. This is the first EPA submission for Microcyn technology in the United States.

In March 2003, Microcyn received CE approval under the European Medical Device Directive 93/42/EEC. The newly obtained CE Mark is based on compliance with the recently developed EN 13727 European test for bactericidal efficacy. Under the supervision of the Dutch notified body (TNO), Microcyn is one of the first disinfectants to meet these new, more rigorous standards in Europe.

The Mexican Ministry of Health approved Microcyn as a disinfectant, sterilant and an antiseptic. In Mexico, Microcyn has been used to treat a number of traumatic wounds including diabetic foot ulcers, varicose vein leg ulcers as well as second and third degree burns.

"Our successful filing with EPA is the first step towards opening the U.S. market," said Alimi, who founded the company in 1999, "And we are excited at the prospect of introducing Microcyn technology as a powerful and user-friendly disinfectant in the U.S."

About Oculus

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative life sciences and disruptive technologies that globally re-define the disinfectant and antiseptic markets. The company has employees and operations in Mexico, Europe and the U.S. and includes two wholly owned subsidiaries, Oculus Technologies of Mexico, S.A. de C.V., and Oculus Innovative Sciences

Netherlands B.V. Please visit us at www.oculusis.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.

Disclaimer

This release concerns a use that has not been approved or cleared by the Food and Drug Administration or the Environmental Protection Agency.